Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.
Read Full NewsA phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.
In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.
A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.
Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma
Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention
6 Ophthalmology Headlines You Missed in October 2025
1.
Guidelines for patient training and radiation protection for patients treated with radioactive iodine for thyroid cancer
2.
Targeted Combination Shows Promise in Metastatic Kidney Cancer
3.
Base-edited T-cell therapy offers additional hope for treating resistant leukemia.
4.
Squeezing through tiny blood vessels may trigger melanoma cells to spread
5.
Childhood brain tumors develop early in highly specialized nerve cells, research reveals
1.
Mastering Oncology RCM: Reducing Errors, Denials & Improving Billing Efficiency
2.
Myeloproliferative Disorders: Causes, Symptoms and Treatment Options
3.
The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review
4.
The Algorithmic Revolution: How AI is Reshaping Precision Oncology from Bench to Bedside
5.
Surprising Symptoms of Prostate Cancer: What You Need to Know
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
5.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge